NO20074767L - Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes - Google Patents

Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes

Info

Publication number
NO20074767L
NO20074767L NO20074767A NO20074767A NO20074767L NO 20074767 L NO20074767 L NO 20074767L NO 20074767 A NO20074767 A NO 20074767A NO 20074767 A NO20074767 A NO 20074767A NO 20074767 L NO20074767 L NO 20074767L
Authority
NO
Norway
Prior art keywords
diabetes
rimonabant
prevention
treatment
type
Prior art date
Application number
NO20074767A
Other languages
English (en)
Inventor
Corinne Hanotin
Pierre Rosenzweig
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/fr
Priority claimed from FR0504942A external-priority patent/FR2882264A1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20074767L publication Critical patent/NO20074767L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører anvendelsen av rimonabant, enten alene eller kombinert med en annen aktiv ingrediens, for fremstillingen av medikamenter som kan anvendes i forbyggingen og behandlingen av type 2 diabetes eller ikke-insulin avhengig diabetes og/eller komplikasjonene derav.
NO20074767A 2005-02-21 2007-09-18 Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes NO20074767L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
PCT/FR2006/000376 WO2006087481A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Publications (1)

Publication Number Publication Date
NO20074767L true NO20074767L (no) 2007-11-20

Family

ID=36218441

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074767A NO20074767L (no) 2005-02-21 2007-09-18 Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes

Country Status (9)

Country Link
US (2) US20080015229A1 (no)
EP (1) EP1853264A1 (no)
KR (1) KR20070104913A (no)
AR (1) AR053812A1 (no)
AU (1) AU2006215444A1 (no)
CA (1) CA2597245A1 (no)
NO (1) NO20074767L (no)
UY (1) UY29386A1 (no)
WO (1) WO2006087481A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP8509A (en) * 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
US20080015229A1 (en) 2008-01-17
WO2006087481A1 (fr) 2006-08-24
AR053812A1 (es) 2007-05-23
CA2597245A1 (fr) 2006-08-24
KR20070104913A (ko) 2007-10-29
EP1853264A1 (fr) 2007-11-14
US20090197917A1 (en) 2009-08-06
AU2006215444A1 (en) 2006-08-24
UY29386A1 (es) 2006-10-02

Similar Documents

Publication Publication Date Title
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2007084314A3 (en) MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
PH12013501790B1 (en) Use of dpp iv inhibitors
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
UA100111C2 (ru) Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
WO2005103002A3 (de) Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel
WO2008148573A3 (de) Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen
EP1935418A4 (en) COMPOSITION FOR ALLEVIATING FATIGUE SUBJECTIVE SYMPTOMS
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
CL2008000982A1 (es) Compuestos derivados de 5-oxo-isoxazol-carboxamida; proceso de preparacion; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de
WO2008090209A3 (en) Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
EP2193789B8 (en) The application of 5-methyl-1,3-benzenediol or derivatives thereof in the preparation of medicines and functional foods for treatment or prevention of depression
WO2010044581A3 (ko) N1-벤조[1,3]다이옥솔-5-일메틸-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
WO2009047788A3 (en) Topical composition containing the combination of mupirocin and beclomethasone
UA88941C2 (ru) Замещенные 4-фенилтетрагидроизохинолины, их применение как лекарственных средств, а также лекарственные средства, которые их содержат
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application